Literature DB >> 15170000

The seroepidemiology of herpes simplex virus type 1 and 2 in Europe.

R G Pebody1, N Andrews, D Brown, R Gopal, H De Melker, G François, N Gatcheva, W Hellenbrand, S Jokinen, I Klavs, M Kojouharova, T Kortbeek, B Kriz, K Prosenc, K Roubalova, P Teocharov, W Thierfelder, M Valle, P Van Damme, R Vranckx.   

Abstract

OBJECTIVES: To describe the seroepidemiology of herpes simplex virus (HSV) types 1 and 2 in the general populations of eight European countries to better understand recent reported changes in disease epidemiology.
METHODS: Belgium, Bulgaria, Czech Republic, England and Wales, Finland, Germany, Netherlands, and Slovenia conducted national cross sectional serological surveys for HSV-1 and HSV-2 between 1989 and 2000. Survey sizes ranged from 3000 to 7166 sera. External quality control was ensured through reference panel testing.
RESULTS: Large intercountry and intracountry differences in HSV-1 and HSV-2 seroprevalence were observed. Age standardised HSV-1 seroprevalence ranged from 52% in Finland, to 57% in the Netherlands, 67% in Belgium, 81% in Czech Republic, and 84% in Bulgaria. Age standardised (>12 years) HSV-2 seroprevalence ranged from 24% in Bulgaria, to 14% in Germany, 13% in Finland, 11% in Belgium, 9% in Netherlands, 6% in Czech Republic, and 4% in England and Wales. In all countries, probability of seropositivity for both infections increased with age. A large proportion of teenagers and young adults remain HSV-1 susceptible particularly in northern Europe. Women were significantly more likely to be HSV-2 seropositive in six of seven (p<0.05) countries and HSV-1 seropositive in four of seven (p<0.05) countries, particularly in northern Europe. No significant evidence of a protective role of HSV-1 for HSV-2 infection was found adjusting for age and sex (p<0.05).
CONCLUSIONS: There is large variation in the seroepidemiology of HSV-1 and HSV-2 across Europe. The observation that a significant proportion of adolescents are now HSV-1 susceptible may have implications for transmission and clinical presentation of HSV-1 and HSV-2.

Entities:  

Mesh:

Year:  2004        PMID: 15170000      PMCID: PMC1744847          DOI: 10.1136/sti.2003.005850

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  43 in total

1.  [The Federal Health Survey: response, composition of participants and non-responder analysis].

Authors:  W Thefeld; H Stolzenberg; B M Bellach
Journal:  Gesundheitswesen       Date:  1999-12

2.  A monoclonal blocking EIA for herpes simplex virus type 2 antibody: validation for seroepidemiological studies in Africa.

Authors:  R Gopal; T Gibbs; M J Slomka; J Whitworth; L M Carpenter; A Vyse; D W Brown
Journal:  J Virol Methods       Date:  2000-06       Impact factor: 2.014

3.  Evaluation of an enzyme immunoassay system for measuring herpes simplex virus (HSV) type 1-specific and HSV type 2-specific IgG antibodies.

Authors:  H E Prince; C E Ernst; W R Hogrefe
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

4.  [Incidence of herpes neonatorum in Netherlands].

Authors:  M A Gaytant; E A Steegers; P L van Cromvoirt; B A Semmekrot; J M Galama
Journal:  Ned Tijdschr Geneeskd       Date:  2000-09-16

5.  Longitudinal study of genital infection by herpes simplex virus type 1 in Western Scotland over 15 years.

Authors:  Anne Scoular; John Norrie; Graeme Gillespie; Noreen Mir; W F Carman
Journal:  BMJ       Date:  2002-06-08

6.  Incidence of herpes simplex virus type 2 infection in the United States.

Authors:  G L Armstrong; J Schillinger; L Markowitz; A J Nahmias; R E Johnson; G M McQuillan; M E St Louis
Journal:  Am J Epidemiol       Date:  2001-05-01       Impact factor: 4.897

7.  Seroprevalence of herpes simplex virus type 1 and type 2 in selected German populations-relevance for the incidence of genital herpes.

Authors:  P Wutzler; H W Doerr; I Färber; U Eichhorn; B Helbig; A Sauerbrei; A Brandstädt; H F Rabenau
Journal:  J Med Virol       Date:  2000-06       Impact factor: 2.327

8.  First episodes of genital herpes in a Swedish STD population: a study of epidemiology and transmission by the use of herpes simplex virus (HSV) typing and specific serology.

Authors:  G B Löwhagen; P Tunbäck; K Andersson; T Bergström; G Johannisson
Journal:  Sex Transm Infect       Date:  2000-06       Impact factor: 3.519

9.  The burden of infection with HSV-1 and HSV-2 in England and Wales: implications for the changing epidemiology of genital herpes.

Authors:  A J Vyse; N J Gay; M J Slomka; R Gopal; T Gibbs; P Morgan-Capner; D W Brown
Journal:  Sex Transm Infect       Date:  2000-06       Impact factor: 3.519

10.  Changing trends in genital herpes simplex virus infection in Bergen, Norway.

Authors:  A Nilsen; H Myrmel
Journal:  Acta Obstet Gynecol Scand       Date:  2000-08       Impact factor: 3.636

View more
  55 in total

1.  Evidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa.

Authors:  Timothy E Dudek; Ernesto Torres-Lopez; Clyde Crumpacker; David M Knipe
Journal:  J Infect Dis       Date:  2011-04-14       Impact factor: 5.226

Review 2.  Current management and recommendations for access to antiviral therapy of herpes labialis.

Authors:  Anthony Cunningham; Paul Griffiths; Peter Leone; Adrian Mindel; Rajul Patel; Lawrence Stanberry; Richard Whitley
Journal:  J Clin Virol       Date:  2011-09-01       Impact factor: 3.168

Review 3.  HSV-2 serology can be predictive of HIV epidemic potential and hidden sexual risk behavior in the Middle East and North Africa.

Authors:  Laith J Abu-Raddad; Joshua T Schiffer; Rhoda Ashley; Ghina Mumtaz; Ramzi A Alsallaq; Francisca Ayodeji Akala; Iris Semini; Gabriele Riedner; David Wilson
Journal:  Epidemics       Date:  2010-09-15       Impact factor: 4.396

4.  Treating HSV and CMV reactivations in critically ill patients who are not immunocompromised: con.

Authors:  G Chanques; S Jaber
Journal:  Intensive Care Med       Date:  2014-11-01       Impact factor: 17.440

Review 5.  The Type I Interferon Response and Age-Dependent Susceptibility to Herpes Simplex Virus Infection.

Authors:  Daniel Giraldo; Douglas R Wilcox; Richard Longnecker
Journal:  DNA Cell Biol       Date:  2017-03-09       Impact factor: 3.311

6.  Risk of herpes simplex virus type 2 acquisition increases over early adulthood: evidence from a cohort study.

Authors:  N Dickson; T van Roode; P Herbison; J Taylor; A Cunningham; C Paul
Journal:  Sex Transm Infect       Date:  2006-08-17       Impact factor: 3.519

7.  High seroprevalence of herpes simplex virus type 2 infection in French human immunodeficiency virus type 1-infected outpatients.

Authors:  Laurent Andréoletti; Emmanuel Piednoir; Jérôme Legoff; Véronique Brodard; Isabelle Beguinot; Christophe Strady; Christine Rouger; Christophe Piketty; Ali Si-Mohamed; Michel Daniel Kazatchkine; Jean-Elie Malkin; Laurent Bélec
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

8.  Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma.

Authors:  Michael Mullerad; Bernard H Bochner; Prasad S Adusumilli; Amit Bhargava; Eiji Kikuchi; Chen Hui-Ni; Michael W Kattan; Ting-Chao Chou; Yuman Fong
Journal:  J Urol       Date:  2005-08       Impact factor: 7.450

9.  How safe is safer sex? High levels of HSV-1 and HSV-2 in female sex workers in London.

Authors:  J Fox; G P Taylor; S Day; J Parry; H Ward
Journal:  Epidemiol Infect       Date:  2006-03-29       Impact factor: 2.451

10.  Type specific seroprevalence of HSV-1 and HSV-2 in four geographical regions of Poland.

Authors:  J S Smith; M Rosinska; A Trzcinska; J M Pimenta; B Litwinska; J Siennicka
Journal:  Sex Transm Infect       Date:  2006-04       Impact factor: 3.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.